New Research May Help Curb Racial Disparities in Kidney Disease Diagnosis, Treatment
Research shows that removing a race modifier from a formula used to diagnose kidney disease may lead to equitable care for Black patients.
Research shows that removing a race modifier from a formula used to diagnose kidney disease may lead to equitable care for Black patients.
Rhabdomyolysis (rhabdo for short) is a sometimes fatal condition caused by overexertion that results in overtaxed muscle cells bursting and dying, releasing toxins into the body. Experts worry many people returning to the gym after a COVID-19 pandemic hiatus might push themselves too hard and wind up diagnosed with rhabdo, reports the Washington Post.
The National Kidney Foundation, the American Society for Clinical Pathology, and the nation’s leading laboratories and clinical laboratory associations have announced a collaboration to remove barriers to testing for chronic kidney disease.
Ortho-Clinical Diagnostics has announced the availability of the NephroCheck test system, the first such test designed to help healthcare providers identify patients at risk of developing moderate or severe acute kidney injury within 12 hours of assessment.
Read MoreWith the prevalence of diabetes continuing on an upward trajectory both in the United States and overseas, healthcare professionals are continuing to search for more effective methods of preventing, detecting, and treating the disease.
Read MoreFDA has granted market clearance for the first test that can help determine whether membranous glomerulonephritis is due to the body’s rejection of its own kidney tissue (autoimmune) or to another cause, such as infection.
Read MoreThe company produces comprehensive third-party designer drug quality controls for use with any methodology, on any testing platform.
Read MoreExamining 12 major types of cancer, scientists at Washington University School of Medicine in St Louis have identified 127 repeatedly mutated genes that appear to drive the development and progression of a range of tumors in the body.
Read MoreResearchers at Moffitt Cancer Center, Tampa, Fla, and colleagues at the University of South Florida have discovered a mechanism that explains how some cancer cells hijack a biological process to potentially activate cell growth and the survival of cancer gene expression.
Read MoreThroughout 2012, the American Association for Clinical Chemistry will be exploring best laboratory practices for detecting and managing four high-prevalence disease states.
Read MoreThe American Association for Clinical Chemistry (AACC) will host 12 Webinars on high-value tests for high-impact diseases.
Read MoreTesting options are growing with the proliferation of HbA1c.
Read MoreWith the participation of the two largest US dialysis companies, Rockwell Medical will conduct two pivotal Phase 3 trials for Soluble Ferric Pyrophosphate as a continuous iron-replacement therapeutic.
Read MoreFormer US Senate majority leader Bill Frist, MD, sits down with CLP to discuss what personalized medicine will mean for labs.
Read MoreThis month, CLP is publishing its first Tech Guide devoted to pathology systems, both traditional anatomic pathology systems as well as the emerging digital technologies. At present, digital pathology accounts for an estimated 1% of the
Read MoreHealthy adults with higher levels of phosphate in the blood are more likely to have increased levels of calcium in the coronary arteries.
Read MoreA National effort is underway to combat chronic kidney disease in North America by offering physicians patient-specific clinical guidance. The program corresponds to newly passed legislation aimed at combating the disease.
Read MoreAnti-Prostate Specific Antigen AVAILABLE CONCENTRATED AND AS A REAGENT BioGenex, San Ramon, Calif, polyclonal anti-Prostate Specific Antigen antibody is designed for the specific localization of Prostate Specific Antigen (PSA) in fo
Read More